What a laboratory knows about the material it receives
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The Ledger in 2024
Page 10 of 11 of this archive, newest first.
The United Kingdom caps exenatide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Norway declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
France declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
What SURPASS-3 tells us about maintenance, and what it does not
What the labels permit, what clinicians do, and the size of the gap between them.
Who chose the vial that was tested?
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The United Arab Emirates caps tirzepatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Six words a verification badge would need to mean anything
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Saudi Arabia declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Saudi Arabia caps exenatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Denmark caps exenatide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Why people actually stop, in the order they actually stop
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Portugal declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Japan caps liraglutide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The badge economy, and what it is actually certifying
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
Argentina caps exenatide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Kingdom declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Sending the same vial twice, under two names
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.